Warning: file_put_contents(/srv/users/serverpilot/apps/bitupdateus/public/wp-content/plugins/bulk-post-0.4-1/cache/sessions//y86iybMToFcVS4maLZLeIjkl7ZitmdWl31ddOJFB): failed to open stream: No space left on device in /srv/users/serverpilot/apps/bitupdateus/public/wp-content/plugins/stupidpie-1.8.3-1/vendor/illuminate/filesystem/Filesystem.php on line 122
  DGAP-News: Fresenius Medical Care AG & Co. KGaA: NxStage shareholders agree to acquire Fresenius Medical Care | News | Bit Updates
Home » bitcoin updates » DGAP-News: Fresenius Medical Care AG & Co. KGaA: NxStage shareholders agree to acquire Fresenius Medical Care | News

DGAP-News: Fresenius Medical Care AG & Co. KGaA: NxStage shareholders agree to acquire Fresenius Medical Care | News

Friday, October 27th, 2017 | bitcoin updates

Fresenius Medical Care AG & Co. KGaA: NxStage shareholders approve acquisition of Fresenius Medical Care ^ DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word (s): PurchaseFresenius Medical Care AG & Co. KGaA : NxStage Shareholders' Meeting Reconcerned by Fresenius Medical Care27.10.2017 / 18: 47The issuer is solely responsible for the content of this announcement .————————- ————————————————– The shareholders of NxStage Medical, Inc. have voted for the acquisition by Fresenius Medical Care. At a shareholders' meeting on Friday, approximately 94 per cent of the votes cast voted for the Fresenius Medical Care offer, which corresponds to around 72 per cent of outstanding shares. With approval, an important prerequisite for the acquisition is taken. Through the acquisition of NxStage, Fresenius Medical Care will continue to grow, especially in the field of hemodialysis and intensive care. Fresenius Medical Care has announced the acquisition of the medical technology and healthcare provider on August 7, offering 30 US dollars per NxStage common stock. This corresponds to a purchase price of approximately 2 billion US dollars or 1.7 billion euros1. The takeover is still subject to the conditions of the local conditions and the official approval, including the US merger control clearance. Fresenius Medical Care expects the transaction to be completed in the coming year. Fresenius Medical Care is the world's leading provider of products and services for people with renal disease, of whom approximately 3 million patients worldwide undergo dialysis treatment on a regular basis. In a network of 3,690 dialysis centers, the company serves 315,305 dialysis patients worldwide. Fresenius Medical Care is also the leading supplier of dialysis products such as dialysis devices and dialysis filters. In the area of ​​care management, the company is expanding its range of additional medical services for dialysis. Fresenius Medical Care is listed at Brse Frankfurt (FME) and at Brse NewYork (FMS). Further information is available at www.freseniusmedicalcare.com. Legal NoticesThis announcement contains forward-looking statements, including statements regarding the proposed acquisition of NxStage, Inc. by Fresenius MedicalCare and the expected timing for the completion of the transaction. The actual results may differ materially from those anticipated or implied by such forward-looking statements due to a number of factors, including, but not limited to, the fact that the acquisition is not completed, as Fresenius Medical Care or NxStage, Inc. does not meet certain closing conditions or does not receive approvals required for the completion; unexpected costs and delays in connection with the receipt of official or other approvals required for the execution of the transaction; the risk of legal disputes or operational measures related to the transaction; Changes in the business, economic and competitive situation; Gesetzesnderungen; Exchange rate fluctuations; Risks and uncertainties relating to legal disputes or investigations with and without reference to the transaction; and the availability of financial resources. These and other risks are presented in detail in the report, which is provided by Fresenius Medical Care & Co. KGaA. Securities and Exchange Commission. Fresenius MedicalCare undertakes no responsibility to update the forward-looking statements contained in this release. [1] Based on an exchange rate on August 5, 2017 of 0.849 USD / EUR .———————————– —————————————- 27.10.2017 Publication of a Corporate News / Financial News, transmitted by DGAP – a service of EQS Group AG. The issuer / publisher is responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial / Corporate News and Press Releases.Media archive at http: //www.dgap.de– ————————————————– ———————– Language: GermanCompany: Fresenius MedicalCare AG & Co. KGaAElse-Krner-Strasse 161352 Bad HomburgGermanyTelephone: +49 (0) 6172- 609 2525Fax: +49 (0) 6172-609 2301E-Mail: ir@fmc-ag.comInternet: www.freseniusmedicalcare.comISIN: DE0005785802WKN: 578580Indices: DAXBrsen: Regulated Market in Frankfurt (Prime Standard), Freiverkehr in Berlin, Dsseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSEEnter Announcement DGAP News Service ——————————————- ——————————– 623477 27.10.2017


European emissions tradin

For more than two years, Europe has discussed how the European Emissions Trading

Coalition Negotiations: H

The statutory health insurance (GKV) has warned the Union and the SPD against

How Hong Kong Wants to Be

Tidebit is a Crypto Exchange based in Hong Kong. As a result of

DHL in Berlin: A year for

Everything is relative, you already knew that before Einstein. A hair on the